{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T14:06:14Z","timestamp":1784124374049,"version":"3.55.0"},"reference-count":105,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Onkologiska Klinikernas i Link\u00f6ping forskningsfond"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The use of oral antineoplastic therapies has accelerated in recent years. Non-supervised administration of oncological therapies introduces uncertainty in regard to adherence. This review and meta-analysis reports on available literature relating to adherence, adherence-measuring methods, interventions to improve adherence, and estimates patient adherence to common oral antineoplastic therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A literature search was conducted in the PubMed database up to January 29, 2024 using relevant terminology for oral antineoplastic agents. Titles and abstracts of retrieved articles were screened, and full-text articles deemed of interest were reviewed. Studies suitable for meta-analysis and consistent with the analytical approach were selected based on adherence measurement methods and definitions. Random effects meta-analysis was conducted using the R package metafor and visualized with forest plots for cumulative adherence and lower-bound adherence separately.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified eight reviews and 75 original studies on adherence to non-endocrine oral antineoplastic agents, spanning the years from 1987 to 2023, with the vast majority published from 2010 onward. This review estimates the cumulative adherence to oral antineoplastic agents to be 84% (95% CI, 78\u201389) and lower-bound adherence as 71% (95% CI, 63\u201378).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The definition of non-adherence and the measurement methods used across studies vary, rendering the comprehensive understanding of the subject challenging. This review identifies an adherence rate that deviates from full compliance across a wide variety of treatment regimens and tumor types, which could provide valuable insights for healthcare professionals in optimizing patient management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag168","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T11:24:54Z","timestamp":1777289094000},"source":"Crossref","is-referenced-by-count":1,"title":["Adherence to oral antineoplastic agents, an overview and meta-analysis"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6399-8368","authenticated-orcid":false,"given":"David","family":"Mourath","sequence":"first","affiliation":[{"name":"Department of Oncology, Link\u00f6ping University Hospital , Link\u00f6ping, 58185,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4336-0949","authenticated-orcid":false,"given":"Helena","family":"Fohlin","sequence":"additional","affiliation":[{"name":"Regional Cancer Center Southeast Sweden , Link\u00f6ping, 58185,","place":["Sweden"]},{"name":"Department of Biomedical and Clinical Sciences, Link\u00f6ping University , Link\u00f6ping, 58185,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"2026060406342240500_oyag168-B1","year":"2012"},{"key":"2026060406342240500_oyag168-B2","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.6004\/jnccn.2008.2003","article-title":"NCCN task force report: oral chemotherapy","volume":"6 Suppl 3","author":"Weingart","year":"2008","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"2026060406342240500_oyag168-B3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000216942","article-title":"Phase II study of vinorelbine by oral route (in a hard gelatine capsule) for metastatic breast cancer patients. A trial of the phase I\/II study group of the Association for Medical Oncology of the German Cancer Society","volume":"14","author":"Queisser","year":"1991","journal-title":"Onkologie"},{"key":"2026060406342240500_oyag168-B4","first-page":"274","article-title":"Etoposide: an update","volume":"8","author":"Fleming","year":"1989","journal-title":"Clin Pharm"},{"key":"2026060406342240500_oyag168-B5","author":"Regionala cancercentrum i samverkan","year":"2024"},{"key":"2026060406342240500_oyag168-B6","author":"World Health Organization","year":"2003"},{"key":"2026060406342240500_oyag168-B7","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1002\/ajh.22019","article-title":"Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia","volume":"86","author":"Ganesan","year":"2011","journal-title":"Am J Hematol"},{"key":"2026060406342240500_oyag168-B8","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026060406342240500_oyag168-B9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.urology.2022.07.012","article-title":"Oral anticancer agent (OAA) adherence and survival in elderly patients with metastatic renal cell carcinoma (mRCC)","volume":"168","author":"Dinan","year":"2022","journal-title":"Urology"},{"key":"2026060406342240500_oyag168-B10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10549-016-3928-3","article-title":"Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a population-based study","volume":"159","author":"Valachis","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"2026060406342240500_oyag168-B11","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1111\/bcp.15147","article-title":"Association between adherence to oral therapies in cancer patients and clinical outcome: a systematic review of the literature","volume":"88","author":"Lasala","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2026060406342240500_oyag168-B12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2165\/00019053-200725060-00004","article-title":"Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia","volume":"25","author":"Darkow","year":"2007","journal-title":"Pharmacoeconomics"},{"key":"2026060406342240500_oyag168-B13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1185\/03007990903396469","article-title":"Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients","volume":"26","author":"Wu","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"2026060406342240500_oyag168-B14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"2026060406342240500_oyag168-B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"2026060406342240500_oyag168-B16","author":"R Core Team","year":"2023"},{"key":"2026060406342240500_oyag168-B17","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1634\/theoncologist.2015-0405","article-title":"A systematic review of adherence to oral antineoplastic therapies","volume":"21","author":"Greer","year":"2016","journal-title":"Oncologist"},{"key":"2026060406342240500_oyag168-B18","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/jnci\/94.9.652","article-title":"Adherence to therapy with oral antineoplastic agents","volume":"94","author":"Partridge","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2026060406342240500_oyag168-B19","doi-asserted-by":"publisher","first-page":"202","DOI":"10.2165\/00003088-199427030-00004","article-title":"Role of patient compliance in clinical pharmacokinetics. A review of recent research","volume":"27","author":"Urquhart","year":"1994","journal-title":"Clin Pharmacokinet"},{"key":"2026060406342240500_oyag168-B20","doi-asserted-by":"publisher","first-page":"981","DOI":"10.2147\/CLEP.S333534","article-title":"Measuring medication adherence in a Population-Based asthma administrative pharmacy database: a systematic review and Meta-Analysis","volume":"13","author":"Asamoah-Boaheng","year":"2021","journal-title":"Clin Epidemiol"},{"key":"2026060406342240500_oyag168-B21","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","article-title":"Adherence to medication","volume":"353","author":"Osterberg","year":"2005","journal-title":"N Engl J Med"},{"key":"2026060406342240500_oyag168-B22","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1200\/JCO.1993.11.6.1189","article-title":"Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring","volume":"11","author":"Waterhouse","year":"1993","journal-title":"J Clin Oncol"},{"key":"2026060406342240500_oyag168-B23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/jn\/136.2.479","article-title":"Correction for errors in measuring adherence to prenatal multivitamin\/mineral supplement use among Low-Income Women12","volume":"136","author":"Jasti","year":"2006","journal-title":"J Nutr"},{"key":"2026060406342240500_oyag168-B24","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/bcp.12734","article-title":"Oral antineoplastic agents: how do we care about adherence?","volume":"80","author":"Barillet","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"2026060406342240500_oyag168-B25","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/jch.14718","article-title":"Retraction statement: Predictive validity of a medication adherence measure in an outpatient setting","volume":"25","year":"2023","journal-title":"J Clin Hypertens"},{"key":"2026060406342240500_oyag168-B26","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1200\/JCO.1987.5.9.1469","article-title":"Compliance with oral drug therapy in patients with hematologic malignancy","volume":"5","author":"Levine","year":"1987","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2026060406342240500_oyag168-B27","first-page":"163","article-title":"A tailored nurse coaching intervention for oral chemotherapy adherence","volume":"5","author":"Schneider","year":"2014","journal-title":"J Adv Pract Oncol"},{"key":"2026060406342240500_oyag168-B28","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1038\/bjc.2012.389","article-title":"Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain","volume":"107","author":"Font","year":"2012","journal-title":"Br J Cancer"},{"key":"2026060406342240500_oyag168-B29","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1093\/annonc\/mdx006","article-title":"Adherence to capecitabine in preoperative treatment of stage II and III rectal cancer: do we need to worry?","volume":"28","author":"Font","year":"2017","journal-title":"Ann Oncol"},{"key":"2026060406342240500_oyag168-B30","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1177\/10781552221077258","article-title":"The association between patient satisfaction with information and adherence to oral anticancer agents","volume":"29","author":"Melis","year":"2023","journal-title":"J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract"},{"key":"2026060406342240500_oyag168-B31","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"Noens","year":"2009","journal-title":"Blood"},{"key":"2026060406342240500_oyag168-B32","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1186\/1471-2407-12-474","article-title":"Adherence evaluation of endocrine treatment in breast cancer: methodological aspects","volume":"12","author":"Oberguggenberger","year":"2012","journal-title":"BMC Cancer"},{"key":"2026060406342240500_oyag168-B33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.farma.2022.11.006","article-title":"Adherence and quality of life in patients with chronic lymphocytic leukemia treated with oral antineoplastic drugs","volume":"47","author":"Ochagav\u00eda Sufrategui","year":"2023","journal-title":"Farm Hosp Organo Of Expresion Cient Soc Espanola Farm Hosp"},{"key":"2026060406342240500_oyag168-B34","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3322\/caac.20004","article-title":"Patient adherence and persistence with oral anticancer treatment","volume":"59","author":"Ruddy","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"2026060406342240500_oyag168-B35","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ctrv.2017.05.002","article-title":"Adherence to oral cancer therapy in older adults: the international society of geriatric oncology (SIOG) taskforce recommendations","volume":"57","author":"Mislang","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"2026060406342240500_oyag168-B36","doi-asserted-by":"publisher","first-page":"e34833","DOI":"10.2196\/34833","article-title":"Investigation of intervention solutions to enhance adherence to oral anticancer medicines in adults: Overview of reviews","volume":"8","author":"Dang","year":"2022","journal-title":"JMIR Cancer"},{"key":"2026060406342240500_oyag168-B37","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/jnci\/djz244","article-title":"Interventions to enhance adherence to oral antineoplastic agents: a scoping review","volume":"112","author":"Rosenberg","year":"2020","journal-title":"JNCI J Natl Cancer Inst"},{"key":"2026060406342240500_oyag168-B38","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.canep.2014.03.012","article-title":"Adherence influencing factors in patients taking oral anticancer agents: a systematic review","volume":"38","author":"Mathes","year":"2014","journal-title":"Cancer Epidemiol"},{"key":"2026060406342240500_oyag168-B39","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.leukres.2008.04.018","article-title":"Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase","volume":"33","author":"Kiguchi","year":"2009","journal-title":"Leuk Res"},{"key":"2026060406342240500_oyag168-B40","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1185\/03007995.2010.533648","article-title":"Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia","volume":"26","author":"Wu","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"2026060406342240500_oyag168-B41","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00277-011-1359-0","article-title":"Good adherence to imatinib therapy among patients with chronic myeloid leukemia\u2014a single-center observational study","volume":"91","author":"J\u00f6nsson","year":"2012","journal-title":"Ann Hematol"},{"key":"2026060406342240500_oyag168-B42","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1185\/03007995.2012.705264","article-title":"A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting","volume":"28","author":"Gu\u00e9rin","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"2026060406342240500_oyag168-B43","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/bjc.2012.348","article-title":"Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study","volume":"107","author":"Efficace","year":"2012","journal-title":"Br J Cancer"},{"key":"2026060406342240500_oyag168-B44","doi-asserted-by":"publisher","first-page":"e56813","DOI":"10.1371\/journal.pone.0056813","article-title":"Patient adherence and persistence with imatinib, nilotinib, dasatinib in clinical practice","volume":"8","author":"Santoleri","year":"2013","journal-title":"PLoS One"},{"key":"2026060406342240500_oyag168-B45","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.18553\/jmcp.2014.20.10.1006","article-title":"Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment","volume":"20","author":"Trivedi","year":"2014","journal-title":"J Manag Care Spec Pharm"},{"key":"2026060406342240500_oyag168-B46","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/1078155213520261","article-title":"Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia","volume":"21","author":"Anderson","year":"2015","journal-title":"J Oncol Pharm Pract"},{"key":"2026060406342240500_oyag168-B47","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1111\/jan.12978","article-title":"Impact of tailored patient education on adherence of patients with chronic myeloid leukaemia to tyrosine kinase inhibitors: a randomized multicentre intervention study","volume":"72","author":"Kek\u00e4le","year":"2016","journal-title":"J Adv Nurs"},{"key":"2026060406342240500_oyag168-B48","doi-asserted-by":"publisher","first-page":"E232","DOI":"10.1188\/17.ONF.E232-E240","article-title":"Adherence and coping strategies in outpatients with chronic myeloid leukemia receiving oral tyrosine kinase inhibitors","volume":"44","author":"Hefner","year":"2017","journal-title":"Oncol Nurs Forum"},{"key":"2026060406342240500_oyag168-B49","doi-asserted-by":"publisher","first-page":"148","DOI":"10.6004\/jadpro.2021.12.2.3","article-title":"A Pharmacist-Led oral chemotherapy program\u2019s impact on chronic myeloid leukemia patient satisfaction, adherence, and outcomes","volume":"12","author":"Dennison","year":"2021","journal-title":"J Adv Pract Oncol"},{"key":"2026060406342240500_oyag168-B50","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1200\/JCO.1992.10.6.1007","article-title":"Patient compliance with oral chemotherapy as assessed by a novel electronic technique","volume":"10","author":"Lee","year":"1992","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2026060406342240500_oyag168-B51","doi-asserted-by":"publisher","first-page":"e12413","DOI":"10.1111\/ecc.12413","article-title":"Do patients on oral chemotherapy have sufficient knowledge for optimal adherence? A mixed methods study","volume":"26","author":"Arber","year":"2017","journal-title":"Eur J Cancer Care"},{"key":"2026060406342240500_oyag168-B52","doi-asserted-by":"publisher","first-page":"e1475\u201383","DOI":"10.1200\/OP.22.00008","article-title":"Medication adherence among adults with comorbid chronic conditions initiating oral anticancer agent therapy for multiple myeloma","volume":"18","author":"Gatwood","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"2026060406342240500_oyag168-B53","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00280-005-0023-6","article-title":"Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a cancer and leukemia group B study","volume":"57","author":"Klein","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026060406342240500_oyag168-B54","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1002\/j.2055-2335.2006.tb00584.x","article-title":"Factors influencing adherence to molecular therapies in haematology-oncology outpatients","volume":"36","author":"Larizza","year":"2006","journal-title":"Pharmacy Practice and Res"},{"key":"2026060406342240500_oyag168-B55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/1097-0142(19900101)65:1&lt;17::aid-cncr2820650106&gt;3.0.co;2-i","article-title":"Patient noncompliance with self-administered chemotherapy","volume":"65","author":"Lebovits","year":"1990","journal-title":"Cancer"},{"key":"2026060406342240500_oyag168-B56","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10549-009-0366-5","article-title":"Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer","volume":"117","author":"Mayer","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"2026060406342240500_oyag168-B57","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1200\/JCO.2009.26.4671","article-title":"Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104","volume":"28","author":"Partridge","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2026060406342240500_oyag168-B58","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1093\/annonc\/mds133","article-title":"Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (adherence companion study 60104 for CALGB 49907)","volume":"23","author":"Ruddy","year":"2012","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2026060406342240500_oyag168-B59","doi-asserted-by":"publisher","first-page":"101780","DOI":"10.1016\/j.ejon.2020.101780","article-title":"Effects of a nurse-led medication self-management programme in women with oral treatments for metastatic breast cancer: a mixed-method randomised controlled trial","volume":"47","author":"Komatsu","year":"2020","journal-title":"Eur J Oncol Nurs Off J Eur Oncol Nurs Soc"},{"key":"2026060406342240500_oyag168-B60","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2147\/PPA.S401480","article-title":"Palbociclib adherence and persistence in patients with hormone receptor positive\/human epidermal growth factor receptor 2 negative (HR+\/HER2-) metastatic breast cancer","volume":"17","author":"Engel-Nitz","year":"2023","journal-title":"Patient Prefer Adherence"},{"key":"2026060406342240500_oyag168-B61","first-page":"1407","article-title":"Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study","volume":"31","author":"Mazzeo","year":"2011","journal-title":"Anticancer Res"},{"key":"2026060406342240500_oyag168-B62","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1159\/000505177","article-title":"Adherence to adjuvant imatinib therapy in patients with gastrointestinal stromal tumor in clinical practice: a cross-sectional study","volume":"64","author":"Wang","year":"2019","journal-title":"Chemotherapy"},{"key":"2026060406342240500_oyag168-B63","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s002800000146","article-title":"Feasibility of a novel weekday-on\/weekend-off oral UFT schedule as postoperative adjuvant chemotherapy for colorectal cancer","volume":"46","author":"Sadahiro","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026060406342240500_oyag168-B64","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2147\/PPA.S80327","article-title":"Patients\u2019 self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis","volume":"9","author":"Kawakami","year":"2015","journal-title":"Patient Prefer Adherence"},{"key":"2026060406342240500_oyag168-B65","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.2147\/PPA.S224496","article-title":"Side effects, self-management activities, and adherence to oral anticancer agents","volume":"13","author":"Jiang","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"2026060406342240500_oyag168-B66","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1248\/yakushi.23-00124","article-title":"Evaluation of the leftover capecitabine tablets in adjuvant CAPOX chemotherapy for gastric cancer","volume":"143","author":"Kimura","year":"2023","journal-title":"Yakugaku Zasshi"},{"key":"2026060406342240500_oyag168-B67","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1185\/03007995.2013.842161","article-title":"Predictors of non-adherence to systemic oral therapy for advanced hepatocellular carcinoma","volume":"29","author":"Mallick","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"2026060406342240500_oyag168-B68","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/bjc.1993.115","article-title":"Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer","volume":"67","author":"Lee","year":"1993","journal-title":"Br J Cancer"},{"key":"2026060406342240500_oyag168-B69","doi-asserted-by":"publisher","first-page":"643","DOI":"10.18553\/jmcp.2017.16389","article-title":"Factors associated with adherence to and treatment duration of erlotinib among patients with non-small cell lung cancer","volume":"23","author":"Hess","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"2026060406342240500_oyag168-B70","first-page":"99","article-title":"Patient compliance with prolonged oral altretamine treatment in relapsed ovarian cancer","volume":"17","author":"Lee","year":"1996","journal-title":"Eur J Gynaecol Oncol"},{"key":"2026060406342240500_oyag168-B71","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1097\/AOG.0000000000004170","article-title":"Adherence to oral anticancer therapeutics in the gynecologic oncology population","volume":"136","author":"Watson","year":"2020","journal-title":"Obstet Gynecol"},{"key":"2026060406342240500_oyag168-B72","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ygyno.2021.08.025","article-title":"Adherence to PARP inhibitor therapy among women with ovarian cancer","volume":"163","author":"Moss","year":"2021","journal-title":"Gynecol Oncol"},{"key":"2026060406342240500_oyag168-B73","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/j.1365-2354.2006.00758.x","article-title":"A comparison of patient adherence and preference of packaging method for oral anticancer agents using conventional pill bottles versus daily pill boxes","volume":"16","author":"Macintosh","year":"2007","journal-title":"Eur J Cancer Care (Engl)"},{"key":"2026060406342240500_oyag168-B74","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1590\/S0103-21002008000200015","article-title":"Factors that affect cancer patient compliance to oral anti-neoplastic therapy","volume":"21","author":"Marques","year":"2008","journal-title":"Acta Paul Enferm"},{"key":"2026060406342240500_oyag168-B75","doi-asserted-by":"publisher","first-page":"E20","DOI":"10.1097\/NCC.0b013e3181b31114","article-title":"A pilot study of an automated voice response system and nursing intervention to monitor adherence to oral chemotherapy agents","volume":"32","author":"Decker","year":"2009","journal-title":"Cancer Nurs"},{"key":"2026060406342240500_oyag168-B76","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1177\/1078155210380292","article-title":"Treatment adherence of cancer patients to orally administered chemotherapy: insights from a Greek study using a self-reported questionnaire","volume":"17","author":"Saratsiotou","year":"2011","journal-title":"J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract"},{"key":"2026060406342240500_oyag168-B77","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000328317","article-title":"Self-reported compliance with capecitabine: findings from a prospective cohort analysis","volume":"80","author":"Winterhalder","year":"2011","journal-title":"Oncology"},{"key":"2026060406342240500_oyag168-B78","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000342087","article-title":"Adherence with oral oncologic treatment in cancer patients: Interest of an adherence score of all dosing errors","volume":"84","author":"Thivat","year":"2013","journal-title":"Oncology"},{"key":"2026060406342240500_oyag168-B79","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1177\/1078155211436022","article-title":"Capecitabine non-adherence: Exploration of magnitude, nature and contributing factors","volume":"18","author":"Bhattacharya","year":"2012","journal-title":"J Oncol Pharm Pract"},{"key":"2026060406342240500_oyag168-B80","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/NCC.0b013e3182551587","article-title":"An intervention to improve adherence and management of symptoms for patients prescribed oral chemotherapy agents: an exploratory study","volume":"36","author":"Spoelstra","year":"2013","journal-title":"Cancer Nurs"},{"key":"2026060406342240500_oyag168-B81","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1590\/s0004-28032014000300004","article-title":"Study on adherence to capecitabine among patients with colorectal cancer and metastatic breast cancer","volume":"51","author":"de Figueiredo Junior","year":"2014","journal-title":"Arq Gastroenterol"},{"key":"2026060406342240500_oyag168-B82","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3923\/ijcr.2015.128.135","article-title":"Impact of patient counseling on medication adherence, beliefs and satisfaction about oral chemotherapies in patients with metastatic cancer at a super specialty hospital","volume":"11","author":"Ramesh","year":"2015","journal-title":"International J. of Cancer Research"},{"key":"2026060406342240500_oyag168-B83","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1188\/15.ONF.647-657","article-title":"Feasibility of a text messaging intervention to promote Self-Management for patients prescribed oral anticancer agents","volume":"42","author":"Spoelstra","year":"2015","journal-title":"Oncol Nurs Forum"},{"key":"2026060406342240500_oyag168-B84","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.3892\/ol.2015.3027","article-title":"Adherence and awareness of the therapeutic intent of oral anticancer agents in an outpatient setting","volume":"9","author":"Kimura","year":"2015","journal-title":"Oncol Lett"},{"key":"2026060406342240500_oyag168-B85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000366226","article-title":"Adherence and patients\u2019 attitudes to oral anticancer drugs: a prospective series of 201 patients focusing on targeted therapies","volume":"88","author":"Barth\u00e9l\u00e9my","year":"2015","journal-title":"Oncology"},{"key":"2026060406342240500_oyag168-B86","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s40064-016-1851-z","article-title":"Adherence assessment of patients with metastatic solid tumors who are treated in an oncology group practice","volume":"5","author":"Feiten","year":"2016","journal-title":"Springerplus"},{"key":"2026060406342240500_oyag168-B87","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1089\/tmj.2015.0126","article-title":"Proof of concept of a mobile health short message service text message intervention that promotes adherence to oral anticancer agent medications: a randomized controlled trial","volume":"22","author":"Spoelstra","year":"2016","journal-title":"Telemed J E-Health Off J Am Telemed Assoc"},{"key":"2026060406342240500_oyag168-B88","doi-asserted-by":"publisher","first-page":"e474\u201385","DOI":"10.1200\/JOP.2016.019729","article-title":"Treatment satisfaction and adherence to oral chemotherapy in patients with cancer","volume":"13","author":"Jacobs","year":"2017","journal-title":"J Oncol Pract"},{"key":"2026060406342240500_oyag168-B89","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1186\/s12913-017-2373-2","article-title":"Impact of pharmacy channel on adherence to oral oncolytics","volume":"17","author":"Stokes","year":"2017","journal-title":"BMC Health Serv Res"},{"key":"2026060406342240500_oyag168-B90","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1177\/1078155216676631","article-title":"Adherence with capecitabine: a population-based analysis based on prescription refill data","volume":"23","author":"Kovacic","year":"2017","journal-title":"J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract"},{"key":"2026060406342240500_oyag168-B91","doi-asserted-by":"publisher","first-page":"204","DOI":"10.7399\/fh.2017.41.2.10596","article-title":"Adherence and safety study in patients on treatment with capecitabine","volume":"41","author":"Fern\u00e1ndez-Ribeiro","year":"2017","journal-title":"Farm Hosp Organo Of Expresion Cient Soc Espanola Farm Hosp"},{"key":"2026060406342240500_oyag168-B92","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1093\/jjco\/hyx087","article-title":"Adherence to oral chemotherapy medications among gastroenterological cancer patients visiting an outpatient clinic","volume":"47","author":"Hirao","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"2026060406342240500_oyag168-B93","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1007\/s00520-017-3584-0","article-title":"The relationship between patient activation, confidence to self-manage side effects, and adherence to oral oncolytics: a pilot study with Michigan oncology practices","volume":"25","author":"Salgado","year":"2017","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"2026060406342240500_oyag168-B94","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1177\/1078155217703792","article-title":"Impact of an integrated oral chemotherapy program on patient adherence","volume":"24","author":"Morgan","year":"2018","journal-title":"J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract"},{"key":"2026060406342240500_oyag168-B95","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1177\/1078155217708022","article-title":"Impact of a specialty pharmacy case management service on adherence in patients receiving oral antineoplastic agents","volume":"24","author":"Middendorff","year":"2018","journal-title":"J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract"},{"key":"2026060406342240500_oyag168-B96","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1177\/1078155216679026","article-title":"Patient perspectives on the barriers associated with medication adherence to oral chemotherapy","volume":"24","author":"Muluneh","year":"2018","journal-title":"J Oncol Pharm Pract"},{"key":"2026060406342240500_oyag168-B97","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.2147\/PPA.S169354","article-title":"Patient-doctor relationship and adherence to capecitabine in outpatients of a German comprehensive cancer center","volume":"12","author":"Hefner","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"2026060406342240500_oyag168-B98","doi-asserted-by":"publisher","first-page":"221","DOI":"10.6004\/jnccn.2018.7098","article-title":"Patient experiences with oral chemotherapy: Adherence, symptoms, and quality of life","volume":"17","author":"Jacobs","year":"2019","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"2026060406342240500_oyag168-B99","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1177\/1078155218800384","article-title":"Adherence to oral chemotherapy: challenges and opportunities","volume":"25","author":"Krikorian","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"2026060406342240500_oyag168-B100","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1007\/s00520-020-05955-3","article-title":"Effectiveness of a nurse-led telephone follow-up in the therapeutic management of patients receiving oral antineoplastic agents: a randomized, multicenter controlled trial (ETICCO study)","volume":"29","author":"Bouleftour","year":"2021","journal-title":"Support Care Cancer Off J Multinatl Assoc Support Care Cancer"},{"key":"2026060406342240500_oyag168-B101","doi-asserted-by":"publisher","first-page":"e378\u201387","DOI":"10.1111\/ajco.13656","article-title":"A smartphone program to support adherence to oral chemotherapy in people with cancer: proof-of-concept trial","volume":"18","author":"Skrabal Ross","year":"2022","journal-title":"Asia Pac J Clin Oncol"},{"key":"2026060406342240500_oyag168-B102","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1177\/10781552211035368","article-title":"Influence of the implementation of a multidisciplinary consultation program on adherence to the first ever course of oral antineoplastic treatment in patients with cancer","volume":"28","author":"Feral","year":"2022","journal-title":"J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract"},{"key":"2026060406342240500_oyag168-B103","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1111\/jocn.16170","article-title":"Predictors of oral chemotherapy adherence at home among chinese cancer patients: an observational prospective study","volume":"31","author":"Chen","year":"2022","journal-title":"J Clin Nurs"},{"key":"2026060406342240500_oyag168-B104","doi-asserted-by":"publisher","first-page":"CD000011","DOI":"10.1002\/14651858.CD000011.pub4","article-title":"Interventions for enhancing medication adherence","volume":"2014","author":"Nieuwlaat","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2026060406342240500_oyag168-B105","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5993\/AJHB.40.2.1","article-title":"Meta-analyses of theory use in medication adherence intervention research","volume":"40","author":"Conn","year":"2016","journal-title":"Am J Health Behav"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag168\/68198838\/oyag168.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/6\/oyag168\/68198838\/oyag168.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/6\/oyag168\/68198838\/oyag168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:34:28Z","timestamp":1780569268000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag168\/8666140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":105,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag168","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,4,30]]},"article-number":"oyag168"}}